UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003805
Receipt number R000004596
Scientific Title Improved effects of Budesonide/Formoterol combination therapy (Symbicort) on the residual eosinophilic inflammation in the distal airways of asthmatic patients who used the salmeterol/fluticasone combination drug
Date of disclosure of the study information 2010/06/24
Last modified on 2013/12/05 00:16:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Improved effects of Budesonide/Formoterol combination therapy (Symbicort) on the residual eosinophilic inflammation in the distal airways of asthmatic patients who used the salmeterol/fluticasone combination drug

Acronym

Effects of Budesonide/Formoterol combination therapy (Symbicort) on the distal airway inflammation

Scientific Title

Improved effects of Budesonide/Formoterol combination therapy (Symbicort) on the residual eosinophilic inflammation in the distal airways of asthmatic patients who used the salmeterol/fluticasone combination drug

Scientific Title:Acronym

Effects of Budesonide/Formoterol combination therapy (Symbicort) on the distal airway inflammation

Region

Japan


Condition

Condition

Bronchial asthma

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the improved effects of Symbicort on distal airway inflammation in well-controlled asthmatic patients who used salmeterol/fluticasone combination drug.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

distal airway inflammation in induced sputum (Eosinophil counts, ECP and SPD)

Key secondary outcomes

Asthma related QOL(AQLQ), impulse oscillometry system (IOS), FeNO, Pulmonary function test, Eosinophils in peripheral blood


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

We evaluate the improved effects of Symbicort on the residual airway inflammation in the distal airway of the well-controlled asthmatic patients who used salmeterol/fluticasone combination drug.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients who regularly used salmeterol/fluticasone combination drug more than 3 months.
2. Stable well-controlled asthmatic patients

Key exclusion criteria

1. Past history of asthma attach in the previous 3 months.
2. Past treatments with oral corticosteroids in the previous 2 weeks.
3. Chronic obstructive lung disease (COPD) and other respiratory disease.
4. Severe liver, kidney, heart, hematic and other diseases
5. Inappropriate patients from the doctor's viewpoint

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroyuki Ohbayashi

Organization

JA Tohno Kousei Hospital

Division name

Allergy and Respiratory Medicine

Zip code


Address

76-1, Toki-Cho, Mizunami City, Gifu Pref., 509-6101, Japan

TEL

0572-68-4111

Email

ohbayasi@nn.iij4u.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiroyuki Ohbayashi

Organization

JA Tohno Kousei Hospital

Division name

Allergy and Respiratory Medicine

Zip code


Address

76-1, Toki-Cho, Mizunami City, Gifu Pref., 509-6101, Japan

TEL

0572-68-4111

Homepage URL


Email

ohbayasi@nn.iij4u.or.jp


Sponsor or person

Institute

JA Tohno Kousei Hospital

Institute

Department

Personal name



Funding Source

Organization

JA Tohno Kousei Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 06 Month 24 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2009 Year 12 Month 08 Day

Date of IRB


Anticipated trial start date

2010 Year 01 Month 01 Day

Last follow-up date

2010 Year 07 Month 01 Day

Date of closure to data entry

2010 Year 07 Month 01 Day

Date trial data considered complete

2010 Year 07 Month 01 Day

Date analysis concluded

2010 Year 07 Month 01 Day


Other

Other related information



Management information

Registered date

2010 Year 06 Month 23 Day

Last modified on

2013 Year 12 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004596


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name